Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Chunxiao MaMin LiuWenxin FengHanyu RaoWei ZhangChangwei LiuYue XuZiyi WangYan TengXiao YangLi NiJin XuWei-Qiang GaoBing LuLi LiPublished in: Clinical and translational medicine (2023)
Our results demonstrated that SETD2 inhibits the RAS/ERK signaling pathway by facilitating the transcription of DUSP7 in SMAD4-deficient CRC, which could provide a potential therapeutic target for the treatment of advanced CRC.